Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Cybrexa sees potential in tumor targeting peptides

Despite all of the advances made in treating different cancers over the past several years, there is still significant room for improvement in oncology. That’s...

| By Kelley Gipson

Weekly Roundup – January 20, 2022

See the full Roundup here. What do you know about stock-based compensation? It’s good to get an expert opinion on the subject! Marcum‘s Katie Daiell...

| By Kelley Gipson

Taconic adds humanized immune system model

Taconic Biosciences reports the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic’s widely used HIS portfolio. huNOG-EXL EA...

| By Kelley Gipson

CT colleges launch data science programs

Connecticut colleges are launching data science programs to train a new generation of analytics workers. The University of Connecticut’s board of trustees recently approved a...

| By Kelley Gipson

Wearable COVID-19 detector from Yale samples air

A team of Yale scientists and engineers has developed a wearable COVID-19 detector that samples the air for the virus and can alert users to an exposure. The...

| By Kelley Gipson

Rallybio heads into the clinic

Since Rallybio launched in 2018, the Connecticut-based company has been laser-focused on the development of “transformative therapeutics” for patients suffering from rare and ultra-rare diseases. The leadership...

| By Kelley Gipson

Benefits of MDMA – the Drug in Ecstasy – re PTSD

MDMA (3,4-methylenedioxymethamphetamine) is an active ingredient in the illicit street drug known as ecstasy or molly. People in dance clubs and raves use illicit MDMA...

| By Kelley Gipson

Weekly Roundup – January 13, 2022

Read the full article in your browser here. Insperity, a small business consultant for more than 30 years, provides an array of human resource solutions...

| By Kelley Gipson

Biohaven and Belgium’s KU Leuven in licensing deal

Biohaven acquired exclusive global rights to develop and sell a novel pain drug from Belgium’s KU Leuven university, the New Haven biotech reports. The deal involves...

| By Kelley Gipson

Arvinas to double workforce after Pfizer deal

Arvinas recently signed a blockbuster $2.4 billion deal with Pfizer. The bankroll will fund additional trials of the Arvinas breast cancer drug, alone and in combination...